Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | GAPDH | P04406 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | STAT6 | P42226 | 1/20 | 0.55 |
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.55 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487166 | 0.84 | ADORA1 (0.41) | ADORA3ADORA2AADORA2BADORA1MAPK1 | |
| SCHEMBL250995 | 0.79 | ADORA3 (0.51) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| SCHEMBL25334955 | 0.79 | P2RX3 (0.63) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL8632632 | 0.77 | ADORA3 (0.51) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| SCHEMBL1276059 | 0.75 | PNP (0.47) | ADORA3MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Adenosine SCHEMBL23420216 | 0.71 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL4403412 | 0.71 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL23804425 | 0.71 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL2028876 | 0.71 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Vidarabine SCHEMBL110914 | 0.71 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338464-B2 | Clonal strains of attenuated vaccinia viruses and methods of use thereof | GENELUX CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| CN-114751950-B | Cyclic dinucleotide compounds and methods of use | 免疫传感器公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-118304290-A | Application of Albanol B in preparation of dual-target anti-gout enzyme inhibitor | 兰州理工大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-111194318-B | Solid forms of compounds for modulating kinases | OPNA生物公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230008052-A1 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | GENELUX CORPORATION | 2023-01-12 | — | — | US | disclosed |
| US-20220340613-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | IMMUNESENSOR THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-3429596-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | IMMUNE SENSOR LLC (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114929288-A | Synthetic modified RNA and uses thereof | 西奈山伊坎医学院 | 2022-08-19 | — | — | CN | disclosed |
| CN-114751950-A | Cyclic dinucleotide compounds and methods of use | 免疫传感器公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114450265-A | Cationic lipids and uses thereof | 菲克特生物科学股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-11299512-B2 | Cyclic di-nucleotide compounds and methods of use | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-109475570-B | Cyclic dinucleotide compounds and methods of use | 免疫传感器公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114230625-A | Cyclic dinucleotide compounds and methods of use | 免疫传感器公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299512-B2 | Cyclic di-nucleotide compounds and methods of use | CGAS, PDE7A, PDE11A | ADORA3 246/4885ADORA2A 116/4885ADORA2B 255/4885 |
| US-20220340613-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | CGAS, PDE7A, PDE11A | ADORA3 246/4885ADORA2A 116/4885ADORA2B 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.